These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 10458826)

  • 1. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
    Abramovich CM; Prayson RA
    Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
    Abramovich CM; Prayson RA
    Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
    Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
    Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological analyses of early recurrence and malignant transformation in meningiomas.
    Arai H; Beppu T; Wada T; Yoshida Y; Kubo Y; Suzuki M; Ogawa A
    Brain Tumor Pathol; 1998; 15(1):37-40. PubMed ID: 9879462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma.
    Ho DM; Hsu CY; Ting LT; Chiang H
    Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathologic features predicting recurrence of meningiomas following subtotal resection.
    de la Monte SM; Flickinger J; Linggood RM
    Am J Surg Pathol; 1986 Dec; 10(12):836-43. PubMed ID: 3789250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas.
    Matsuno A; Fujimaki T; Sasaki T; Nagashima T; Ide T; Asai A; Matsuura R; Utsunomiya H; Kirino T
    Acta Neuropathol; 1996; 91(5):504-10. PubMed ID: 8740231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas.
    Karamitopoulou E; Perentes E; Tolnay M; Probst A
    Hum Pathol; 1998 Feb; 29(2):140-5. PubMed ID: 9490273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome.
    Abramovich CM; Prayson RA
    Am J Clin Pathol; 2000 Jul; 114(1):84-92. PubMed ID: 10884803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIB-1 staining index of pediatric meningiomas.
    Sandberg DI; Edgar MA; Resch L; Rutka JT; Becker LE; Souweidane MM
    Neurosurgery; 2001 Mar; 48(3):590-5; discussion 595-7. PubMed ID: 11270550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
    Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
    Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies].
    Miyagami M; Shibuya T; Miyagi A; Tsubokawa T
    No To Shinkei; 1996 Jan; 48(1):39-43. PubMed ID: 8679317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant meningioma: a clinicopathologic study of 23 patients including MIB1 and p53 immunohistochemistry.
    Prayson RA
    Am J Clin Pathol; 1996 Jun; 105(6):719-26. PubMed ID: 8659446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of p53, MDM2 protein and Ki-67 antigen in recurrent meningiomas.
    Ohkoudo M; Sawa H; Hara M; Saruta K; Aiso T; Ohki R; Yamamoto H; Maemura E; Shiina Y; Fujii M; Saito I
    J Neurooncol; 1998 May; 38(1):41-9. PubMed ID: 9540056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative potential of recurrent intracranial meningiomas as evaluated by labelling indices of BUdR and Ki-67, and tumour doubling time.
    Kakinuma K; Tanaka R; Onda K; Takahashi H
    Acta Neurochir (Wien); 1998; 140(1):26-31; discussion 31-2. PubMed ID: 9522904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature.
    Wolfsberger S; Doostkam S; Boecher-Schwarz HG; Roessler K; van Trotsenburg M; Hainfellner JA; Knosp E
    Neurosurg Rev; 2004 Oct; 27(4):238-45. PubMed ID: 15168138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of histological signs of tumor progression in recurrences of completely resected meningiomas.
    Schiffer D; Ghimenti C; Fiano V
    J Neurooncol; 2005 Jun; 73(2):125-30. PubMed ID: 15981101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MCM7 expression is a promising predictor of recurrence in patients surgically resected for meningiomas.
    Winther TL; Torp SH
    J Neurooncol; 2017 Feb; 131(3):575-583. PubMed ID: 27868157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
    Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
    Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study.
    Takeuchi H; Kubota T; Kabuto M; Kitai R; Nozaki J; Yamashita J
    Surg Neurol; 1997 Nov; 48(5):501-6. PubMed ID: 9352816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.